Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Leroy, Vincent; Angus, Peter; Bronowicki, Jean–Pierre; J. Dore, Gregory; Hézode, Christophe; Pianko, Stephen; Pol, Stanislas; Stuart, Katherine; Tse, Edmund; McPhee, Fiona; Bhore, Rafia; Jimenez-Exposito, M.J.; Thompson, Alexander

doi:10.1002/hep.28473

Public

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Published in Hepatology • Jan 29, 2016

Authors:

Vincent Leroy

Peter Angus

Jean–Pierre Bronowicki

Abstract

UNLABELLED: Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination of daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SO...

Subject

Sofosbuvir

Daclatasvir

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!